Blastoid mantle cell lymphoma

Radhia M’kacher(Genopole (France)), Alain Bernheim(Triemli Hospital), Françoise Farace(Institut Gustave Roussy), Bernard Clausse(Centre National de la Recherche Scientifique), Ali G. Turhan(Inserm), D. Violot(Institut Gustave Roussy), Annelise Bennaceur‐Griscelli(Inserm), Patrice Carde(Institut Gustave Roussy), Joseph Dossou(Laboratoire d'études sur les monothéismes), A. Valent(Centre National de la Recherche Scientifique), J. Bosq(Université de Bordeaux), C Parmentier(Institut Gustave Roussy), Vincent Ribrag(Institut Gustave Roussy)

Cancer Genetics and Cytogenetics

May 1, 2003

10.1016/s0165-4608(02)00823-3

Cited by 36

Related Papers

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

|Cancer Discovery|2017|781

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

|The Lancet Oncology|2018|614

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

|The Lancet|2016|401

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

|Blood|2009|269

Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.

|PubMed|2000|267